Download Lyfjagæðavísar - valdar heimildir Open new window

Landlæknisembættið
Gæða- og lýðheilsusvið/Heilbrigðistölfræðisvið
21. apríl 2010
Lyfjagæðavísar: Valdar heimildir
(Raðað í samræmi við ATC-númer viðkomandi gæðavísa og því er um tvítekningar að ræða milli heimilda fyrir
lyf sem notuð eru við sömu sjúkdómum, s.s. heimildir fyrir gæðavísum um þvagræsilyf, Digoxín og lyf sem
hemja renínangíótensín-kerfið).
Unnið á tímabilinu ágúst 2009 til apríl 2010.
Sýruhemjandi lyf (Prótónpumpuhemlar) (A02BA02, A02BC1, A02BC5)
Kóvar (B01AA03)
Digoxín (C01AA05)
Amíódarón (C01BD01)
Þvagræsilyf og lyf sem hemja renínangíótensín-kerfið (C03.. og C09..)
Blóðfitulækkandi lyf (C10AA..)
Thyroxín (H03AA01)
Bólgueyðandi gigtarlyf (M01A..)
Beinþynningarlyf (M05BA.., M05BB..)
Geðrofslyf- sefandi lyf (N05A..)
Þunglyndislyf (SSRI/SNRI og Mirtrazepín) (N06A..)
Sýruhemjandi lyf (Prótónpumpuhemlar) (A02BA02, A02BC1., A02BC5.)
National Institute for Clinical Excellence (NICE) Guidance on Dyspepsia: Managing dyspesia in adults in
primary care. London. NICE 2004. Sótt 20 ágúst 2009 á vef: www.nice.org.uk
Evidence for PPI Use in Gastroesophageal Reflux Disease, Dyspepsia and Peptic Ulcer Disease: Scientific
Report. Canadian Optimal Medication Prescribing and Utilization Service (COMPUS). Canadian Agency for
Drugs and Technologies in Health (CADTH).Volume 1, Issue 2 March 2007. Sótt 20 ágúst 2009 á
vef: http://www.cadth.ca/index.php/en/compus/current-topics/ppis
Genomgången av läkemedel mot sjukdomar orsakade av magsyra
Läkemedelsförmånsnämnden (LFN). Anders Wessling, Douglas Lundin. Januar 2006. Sótt 20 ágúst 2009 á
vef: www.lfn.se
Lothian Joint Formulary. Adult Formulary Update: January 2009. 1.3 Drugs for dyspepsia and GORD. Sótt 18
ágúst 2009 á vef: http://www.ljf.scot.nhs.uk/exist/xmldb/db/ljf_v2/unified/unified1_3.xml
Overprescribing proton pump inhibitors. BMJ 2008;336:2-3 (5 January), doi:10.1136/bmj.39406.449456.BE
Reimer C et al. Proton-Pump Inhibitor Therapy Induces Acid-Related Symptoms in Healthy Volunteers After
Withdrawal of Therapy. Gastroenterology July 2009 (Vol. 137, Issue 1, Pages 80-87.e1)
Evidence That Proton-Pump Inhibitor Therapy Induces the Symptoms it Is Used to Treat , McColl, .K.E.L,
Gillen D. Gastroenterology July 2009 (Vol. 137, Issue 1, Pages 20-22)
Error! Hyperlink reference not valid. Guidelines and Protocols Advisory Committee. British
Columbia. January 30, 2009. Sótt 20 ágúst 2009 á vef:
http://www.bcguidelines.ca/gpac/guideline_gastro.html
NPS News 46: Proton pump inhibitors June 2006. Sótt 30 ágúst 2009 á vef:
http://www.nps.org.au/health_professionals/publications/nps_news/current/proton_pump_inhibitors
Clinical Knowledge Summaries. Dyspepsia - proven gastro-oesophageal reflux disease - Last revised in June
2008. http://www.cks.library.nhs.uk/dyspepsia_proven_gord
The Swedish Council on Technology Assessment in Health Care (SBU). Dyspepsia and reflux. A Systematic
Literature Review. Report no. 185. http://www.sbu.se/sv/Publicerat/Gul/Dyspepsi-och-reflux-/
Institut for Rationel Farmakoterapi. Nationale rekommendationsliste. Institut for Rationel Farmakoterapi.
2007. Sótt 18 ágúst á vef:
http://www.irf.dk/dk/rekommandationsliste/baggrundsnotater/fordoejelse_og_stofskifte/valg_af_laegemidler_
mod_mavesyrerelaterede_forstyre.htm
Institut for Rationel Farmakoterapi. 2007. Behandling af dyspepsi. Sótt 20 ágúst 2009 á vef:
http://www.irf.dk/dk/publikationer/rationel_farmakoterapi/maanedsblad/2007/behandling_af_dyspepsi__specielt_i_primaersektoren.htm
http://www.nzgg.org.nz/guidelines/dsp_guideline_popup.cfm?guidelineCatID=32&guideline
ID=77
1
Landlæknisembættið
Gæða- og lýðheilsusvið/Heilbrigðistölfræðisvið
21. apríl 2010
Prescribing Practice Review - Health Professional Publication July 2006 NPS Prescribing Practice Review 34:
Proton pump inhibitors in primary care
http://www.nps.org.au/health_professionals/publications/prescribing_practice_review/editions/current/prescribi
ng_practice_review_34/proton_pump_inhibitors_in_primary_care
Ip S, Bonis P, Tatsioni A, Raman G, Chew P, Kupelnick B, Fu L, DeVine D, Lau J. Comparative Effectiveness
of Management Strategies for Gastroesophageal Reflux Disease. Comparative Effectiveness Review No. 1.
Agency for Healthcare Research and Quality. December 2005.
http://effectivehealthcare.ahrq.gov/healthInfo.cfm?infotype=rr&ProcessID=1&DocID=42
Gastroesophageal reflux disease (GERD). University of Michigan Health System - Academic Institution. 2002
Mar (revised 2007 Jan). 9.
VHA/DoD clinical practice guideline for the management of adults with gastroesophageal reflux disease in
primary care practice. Department of Defense, Department of Veterans Affairs, Veterans Health Administration
2003 Mar. http://www.guideline.gov/summary/summary.aspx?doc_id=5188
Drug Safety Update: Volume 2 Issue 12, July 2009. Sótt 10 september 2009 á vef:
http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformed
icines/ssLINK/CON051770
Institute for Clinical Systems Improvement. Health Care Guideline: Initial Management of Dyspepsia and
GERD. Seventh Edition. July 2006.
Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture.
JAMA 2006;296:2947-53
Herzig SJ, Howell MD, Ngo LH, Marcantonio ER. Acid-suppressive medication use and the risk for hospitalacquired pneumonia. JAMA. 2009;301:2120-2128. http://jama.ama-assn.org/cgi/content/abstract/301/20/2120
Kóvar (B01AA03)
Atrial fibrillation (CG36). National Institute for health and clinical excellence, NICE, june 2006.
http://www.nice.org.uk/page.aspx?o=cg36
ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation - Full Text. 2006 NA.
http://circ.ahajournals.org/cgi/content/full/114/7/e257
ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation - Executive
Summary. (Circulation. 2006;114:700-752.)
The Management of People with Atrial Fibrillation and Flutter. New Zealand Guidelines Group (NZGG) may
2005.
http://www.nzgg.org.nz/guidelines/dsp_guideline_popup.cfm?guidelineID=85&guideline_popup_mode=index
Arnar DO, Valdimarsson H, Einarsdóttir R, Helgason S, Egilsson T, og Haraldsdóttir V. Klínískar leibeiningar
um blóðþynningu og blóðflöguhemjandi meðferð með gáttatif án lokusjúkdóms. Landlæknisembættið, 2002.
Sótt 20 ágúst á vef: www.landlaeknir.is/pages/124
NPS Prescribing Service. Newsletter no, 62. Using antithrombotics wisely in stroke prevention. 2009. Sótt 20
ágúst á vef: www.nps.org.au
Digoxín (C01AA05)
European Society of Cardiology. ESC guidelines for the diagnosis and treatment of chronic heart failure.
European Heart Journal 2008;29:2388-2442). doi:10.1093/eurheartj/ehn309
National Institute for Clinical Excellence (NICE). Management of chronic heart failure in adults in primary and
secondary care. Clinical guideline. July 2003. Sótt 21 mars 2010 á vef:
http://www.nice.org.uk/cat.asp?c=79725
National Institute for Clinical Excellence (NICE). Management of chronic heart failure in adults in primary and
secondary care. Preliminary draft. Clinical guideline. January 2010. Sótt 21 mars 2010 á vef:
http://www.nice.org.uk/cat.asp?c=79725
Arnold,JM, P Liu, C Demers, et al. Canadian Cardiovascular Society consensus conference recommendations
on heart failure 2006: Diagnosis and management. Can J Cardiol. 2006;22(1):23-45. Sótt 21 mars 2010 á vef:
http://www.ccs.ca/download/consensus_conference/consensus_conference_archives/Arnold_CCS_final.pdf
Guidelines and Protocols Advisory Committee. British Columbia Medical Association. Heart failure care.
February 2008
MeReC Bulletin Volume 18 No 3: Chronic heart failure: overview of diagnosis and drug treatment in primary
care. February 2008. http://www.npc.co.uk/ebt/merec/cardio/heart/merec_bulletin_vol18_no3.html
2
Landlæknisembættið
Gæða- og lýðheilsusvið/Heilbrigðistölfræðisvið
21. apríl 2010
Amíódarón (C01BD01)
Keep an Eye on Amiodarone Patients. Prescriber Update 2005;26(1):5-6
Medsafe Pharmacovigilance Team. Sótt 20 ágúst 2009 á vef
http://www.medsafe.govt.nz/Profs/PUarticles/amiod.htm#Amiodarone
What safety monitoring is required in a patient receiving amiodarone in primary care?
Sótt 20 ágúst 2009 á vef http://www.bettertesting.org.uk/?id=-1166
Using oral amiodarone safely. Drug and Therapeutics Bulletin 2003;41(2):9-11.
Siddoway LA. Amiodarone: Guidelines for use and monitoring. American Family Physician 2003;68:21892196. Sótt 12 apríl 2009 á vef http://www.aafp.org/afp/2003/1201/p2189.html
American Association of Clinical Endocrinologists and the American College of Endocrinology. Clinical
Practice Guidelines for Evaluation and Treatment of Hyperthyroidism and Hypothyroidism 2002 (amended
2006). Sótt 8 apríl 2010 á vef:
http://www.aace.com/pub/pdf/guidelines/hypo_hyper.pdf
Bickford,CL.Spencer,AP.Adherence to the NASPE Guideline for Amiodarone Monitoring at a Medical
University. J Manag Care Pharm. 2006;12(3):254-59
http://www.amcp.org/data/jmcp/Contemporary%20Subject_254-259.pdf
Goldschlager, N., et al., A Practical Guide for Clinicians Who Treat Patients with Amiodarone: 2007. Heart
Rhythm, 2007. 4(9): p. 1250-1259. Sótt 8 apríl 2010 á vef:
http://www.hrsonline.org/Policy/ClinicalGuidelines/ doi:10.1016/j.hrthm.2007.07.020
Goldschlager N, Epstein AE, Naccarelli G, Olshansky B, Singh B. Practical
guidelines for clinicians who treat patients with amiodarone. Practice Guidelines
Subcommittee, North American Society of Pacing and Electrophysiology.
Arch Intern Med. 2000;160:1741-48. http://archinte.ama-assn.org/cgi/content/abstract/160/12/1741
Adverse Drug Reactions Advisory Committee (ADRAC). The multiple toxicities of amiodarone. Aust Adv
Drug React Bull 2005;24:11. http://www.tga.gov.au/adr/aadrb/aadr0506.htm#3
Þvagræsilyf og lyf sem hemja renín angíótensín kerfið (C03.. og C09..)
Matchar DB, McCrory DC, Orlando LA, Patel MR, Patel UD, Patwardhan MB, Powers B. Samsa GP, Gray
RN. Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors (ACEIs) and Angiotensin II
Receptor Antagonists (ARBs) for Treating Essential Hypertension. Comparative Effectiveness Review No. 10.:
Agency for Healthcare Research and Quality.November 2007. Sótt 20 ágúst 2009 á vef:
http://effectivehealthcare.ahrq.gov/healthInfo.cfm?infotype=rr&ProcessID=12&DocID=48
Måttligt förhöjt blodtryck (Moderately Elevated Blood Pressure. A Systematic Literature Review) SBU –
Statens beredning för medicinsk utvärdering. 2007. Sótt 20 ágúst 2009 á vef:
http://www.sbu.se/sv/Publicerat/Gul/Mattligt-forhojt-blodtryck-uppdatering-2007/
National Institute for Clinical Excellence (NICE). Hypertension: management of hypertension in adults in
primary care. Clinical guideline. Júní 2006. Sótt 20 ágúst 2009 á vef:
http://www.nice.org.uk/page.aspx?o=CG34
Scottish Intercollegiate Guidelines Network (SIGN). Management of chronic heart failure. Full guideline. (No.
95). Edinburgh: SIGN; February 2007. Sótt 21 mars 2010 á vef: http://www.sign.ac.uk/pdf/sign95.pdf
Comparative Effectiveness of Medical Therapies with or without ACEs or ARBs for Stable Ischemic Heart
Disease. AHRQ Effective Health Care Program 26 February 2009 Sótt 20 ágúst 2009 á vef:
http://www.effectivehealthcare.ahrq.gov/reports/final.cfm
Musini VM, Fortin PM, Bassett K, Wright JM. Blood pressure lowering efficacy of rennin inhibitors for
primary hypertension. Cochrane Database of Systematic Reviews 2008, Issue 4.
http://www.cochrane.org/reviews/en/ab007066.html
Heran BS, Wong MMY, Heran IK, Wright JM. Blood pressure lowering efficacy of angiotensin receptor
blockers for primary hypertension. Cochrane Database of Systematic Reviews 2008, Issue 4.
Heran BS, Wong MMY, Heran IK, Wright JM. Blood pressure lowering efficacy of angiotensin converting
enzyme (ACE) inhibitors for primary hypertension. Cochrane Database of Systematic Reviews 2008, Issue 4.
Välj ACE-hämmare i första hand framför angiotensinreceptor-blockerare (ARB) - även vid nedsatt
njurfunktion. Kloka Listan, kloka råd. Sótt 20 ágúst 2009 á vef:
http://www.janusinfo.se/imcms/servlet/GetDoc?meta_id=10822
JG Howlett, RS McKelvie, JMO Arnold, et al. Canadian Cardiovascular
Society Consensus Conference guidelines on heart failure, update 2009: Diagnosis and management of rightsided heart failure, myocarditis, device therapy and recent important clinical trials. Can J Cardiol
2009;25(2):85-105.
3
Landlæknisembættið
Gæða- og lýðheilsusvið/Heilbrigðistölfræðisvið
21. apríl 2010
Institute for Rational Farmakoterapy. Vejledningaer 2009. Skift fra angiotensin-2 antagonist til ACE-hæmmer.
http://www.irf.dk/dk/publikationer/vejledninger/skift_fra_angiotensin-2_antagonist_til_acehaemmere_ved_ukompliceret_hypertension.htm
MeReC Bulletin Volume 17 No 01: The management of hypertension in primary care: updated guidance from
NICE. September 2006.
http://www.npc.co.uk/ebt/merec/cardio/cdhyper/resources/merec_bulletin_vol17_no1_whole_document.pdf
Beckett NS, Peters R, Fletcher AE, et al. for the HYVET Study Group. Treatment of hypertension in patients
80 years of age or older. N Engl J Med 2008;358:1887–1898.
European Society of Cardiology. ESC guidelines for the diagnosis and treatment of chronic heart failure.
European Heart Journal 2008;29:2388-2442). doi:10.1093/eurheartj/ehn309
National Institute for Clinical Excellence (NICE). Management of chronic heart failure in adults in primary and
secondary care. Clinical guideline. July 2003. Sótt 21 mars 2010 á vef:
http://www.nice.org.uk/cat.asp?c=79725
National Institute for Clinical Excellence (NICE). Management of chronic heart failure in adults in primary and
secondary care. Preliminary draft. Clinical guideline. January 2010. Sótt 21 mars 2010 á vef:
http://www.nice.org.uk/cat.asp?c=79725
Arnold,JM, P Liu, C Demers, et al. Canadian Cardiovascular Society consensus conference recommendations
on heart failure 2006: Diagnosis and management. Can J Cardiol. 2006;22(1):23-45. Sótt 21 mars 2010 á vef:
http://www.ccs.ca/download/consensus_conference/consensus_conference_archives/Arnold_CCS_final.pdf
Guidelines and Protocols Advisory Committee. British Columbia Medical Association. Heart failure care.
February 2008
MeReC Bulletin Volume 18 No 3: Chronic heart failure: overview of diagnosis and drug treatment in primary
care. February 2008. http://www.npc.co.uk/ebt/merec/cardio/heart/merec_bulletin_vol18_no3.html
Health Benchmarks. Clinical Quality Indicator Specification 2009.
APPROPRIATE MONITORING FOR ANGIOTENSIN CONVERTING ENZYME INHIBITORS,
ANGIOTENSIN RECEPTOR BLOCKERS USE. Joint National Committee on Prevention, Detection,
Evaluation, and Treatment of High Blood Pressure, Seventh Report.
http://www.bcbsil.com/provider/pdf/monitoring_arb.pdf
Health Benchmarks. Clinical Quality Indicator Specification 2009. APPROPRIATE MONITORING FOR
DIURETICS. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood
Pressure, Seventh Report. http://www.bcbsil.com/provider/pdf/monitoring_diuretics.pdf
Blóðfitulækkandi lyf (C10AA..)
Vinnureglur fyrir lyfjaskírteini. Blóðfitulækkandi lyf - 1. mars 2009. Sótt 18 ágúst 2009 á vef
http://www.tr.is/heilsa-og-sjukdomar/lyf/lyfjaskirteini/ )
Fréttabréf lyfjadeildar. 2. Tbl. Blóðfitulækkandi lyf http://eplica.tr.is/media/frettabref/Frettabref2.pdf
National Institute for Health and Clinical Excellence (NICE). Lipid modification. Cardiovascular risk
assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular
disease. CG no. 67. May 2008. Sótt 23 ágúst á vef
http://guidance.nice.org.uk/CG67
Institute for Rational Farmakoterapy (IRF). Kan kolesterolpatienter behandles bedre?
Ja, men sjældent ved brug af dyre statiner. 25 august 2009. Sótt 25 ágúst 2009 á vef
http://www.irf.dk/dk/nyheder/kan_kolesterolpatienter_behandles_bedre.htm
Gitt AK. Trial Data Suggest Wider, More Intensive Statin Use. DYSIS (Dyslipidemia International Study).
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2697103
Pedersen T R, Færgeman O, Kastelein JJP et al. High-Dose Atorvastatin vs Usual-Dose Simvastatin for
Secondary Prevention After Myocardial Infarction: The IDEAL Study: A Randomized Controlled Trial JAMA
2005;294:2437-2445
Ridker P M, Danielson E, M.I.A., Fonseca F A H et al. Rosuvastatin to prevent vascular events in men and
women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207
Opie LH, Commerford PJ, Gersh BJ. Controversies in stable coronary artery disease. Lancet 2006;367:69-78
Hayward R A, Hofer TP Vijan S. Narrative review: Lack of evidence for recommended low-density
lipoprotein treatment targets: A solvable problem. Ann Intern Med 2006;145:520-530.
4
Landlæknisembættið
Gæða- og lýðheilsusvið/Heilbrigðistölfræðisvið
21. apríl 2010
Thyroxín (H03AA01)
Demers LM, Spencer CA for the AACE Thyroid Task Force. American Association of Clinical
Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hyperthyroidism
and hypothyroidism. Endocr Pract. 2002;8:457-469. (amended 2006). Sótt 8 apríl 2010 á vef:
http://www.aace.com/pub/pdf/guidelines/hypo_hyper.pdf
Ladenson PW, Singer PA, Ain KB, et al. American Thyroid Association guidelines for detection of thyroid
dysfunction. Arch Intern Med. 2000;160:1573-1575.
Bólgueyðandi gigtarlyf (M01A..)
National Institute for Health and Clinical Excellence (NICE). Osteoarthritis
The care and management of osteoarthritis in adults. CG no. 59. February 2008. Sótt 23 ágúst á vef
http://guidance.nice.org.uk/CG59
Indicators of Quality Prescribing: 16 - National Prescribing Service Limited. Avoiding the 'Triple Whammy'.
Sótt 18 ágúst 2009 á vef:
http://www.nps.org.au/__data/assets/pdf_file/0003/37407/indicator_16.pdf
Adverse Drug Reactions Advisory Committee. Beware the triple whammy! Australian Adverse Drug Reactions
Bulletin 2006;25:18. Sótt 18 ágúst 2009 á vef: http://www.tga.gov.au/adr/aadrb/aadr0610.pdf
Chan FKL, Suen B, Wong VW, et al. Combination of a cyclooxygenase (COX)-2 selective NSAID and a
proton pump inhibitor for prevention of gastroduodenal ulcers in very high risk patients: a one-year, double
blind, randomized trial. Gastroenterology. 2008;134:A-19.
http://download.journals.elsevierhealth.com/pdfs/journals/0016-5085/PIIS0016508508600979.pdf
Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, et al. Cardiovascular risk associated with
celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071–1080.
http://www.ncbi.nlm.nih.gov/pubmed/15713944?dopt=Abstract
Lanza FL et al. Practice Parameters Committee of the American College of Gastroenterology.Guidelines for
Prevention of NSAID-Related Ulcer Complications. Am J Gastroenterol 2009; 104:728 – 738;Sótt 6 september
á vef: http://www.gi.org/physicians/pdfs/NSAIDJournalPublicationFebruary2009.pdf
Ray WA, Stein CM, Byrd V, et al. Educational program for physicians to reduce use of non-steroidal
antiinflammatory drugs among community-dwelling elderly persons: a randomized controlled trial. Med Care
2001;39:425-35.
Stein CM, Griffin MR, Taylor JA, et al. Educational program for physicians to reduce use of nonsteroidal antiinflammatory drugs among nursing home residents. Med Care 2001;39:436-45.
McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the
observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA. 2006;296(13):16331644
Chen L C, Ashcroft D M. Risk of myocardial infarction associated with selective COX-2 inhibitors: metaanalysis of randomised controlled trials. Pharmacoepidemiology and Drug Safety. 2007;16(7):762-772.
Adverse Drug Reactions Advisory Committee. ACE inhibitor, diuretic and NSAID: a dangerous combination.
Australian Adverse Drug Reactions Bulletin 2003;22:14-5. Sótt 18 ágúst 2009 á vef:
http://www.tga.gov.au/adr/aadrb/aadr0308.pdf
ADRAC, Thomas M. Diuretics, ACE inhibitors and NSAIDs - the triple whammy. MJA 2000; 172: 184-5.
Boyd IW, Mathew TH, Thomas MC. COX-2 inhibitors and renal failure: the triple whammy revisited. MJA
2000; 173: 274 (corr. MJA 2000; 173: 504).
Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients
treated with COX-2 selective and non-selective NSAIDs. Lancet 2005;365:475-81.
Smalley W, Stein CM, Arbogast PG, et al. Underutilization of gastroprotective measures in patients receiving
nonsteroidal antiinflammatory drugs. Arthritis Rheum 2002;46:2195-200.
Scheiman JM, Yeomans ND, Talley NJ et al. (2006) Prevention of ulcers by esomeprazole in at-risk patients
using non-selective NSAIDs and COX-2 inhibitors. American Journal of Gastroenterology 101 (4): 701–10.
NPS Prescribing Service. NPS factsheets for health professionals. Diclofenac and cardiovascular risk
September 2006
http://www.nps.org.au/health_professionals/publications/factsheets/factsheets/diclofenac_and_cardiovascular_r
isk
NPS Prescribing Service. NPS factsheets for health professionals. Switching patients from Vioxx October 2004
http://www.nps.org.au/health_professionals/publications/factsheets/factsheets/switching_patients_from_vioxx
MeReC Extra. National Prescribing Centre. Issue No 30.
5
Landlæknisembættið
Gæða- og lýðheilsusvið/Heilbrigðistölfræðisvið
21. apríl 2010
Cardiovascular and gastrointestinal safety of NSAIDs. November 2007. Sótt 9 september 2009 á vef:
http://www.npc.co.uk/ebt/merec/cardio/cdrisk/merec_extra_no30.htm
Medicines and Healthcare products Regulatory Agency. Cardiovascular safety of COX-2 inhibitors and nonselective NSAIDs.
www.mhra.gov.uk/home/idcplg?IdcService=SS_GET_PAGE&useSecondary=true&ssDocName=CON019582
Chou R, Helfand M, Peterson K, et al. Comparative effectiveness and safety of analgesics for osteoarthritis.
Agency for Healthcare Research and Quality Publication No. 06-EHC009-EF. September 2006. Sótt 6 ágúst á
vef: www.ahrq.gov
Gislason G et al. Increased Mortality and Cardiovascular Morbidity Associated With Use of Nonsteroidal Antiinflammatory Drugs in Chronic Heart FailureArch Intern Med. 2009;169(2):141-149. Sótt 9 september 2009 á
vef: http://archinte.ama-assn.org/cgi/content/abstract/169/2/141
Kearney PM, Baigent C, Godwin J, et al. Do selective cyclo-oxygenase 2 inhibitors and traditional nonsteroidal anti-inflammatory drugs increase the risk of atherothrombosis? A meta-analysis of randomised trials.
BMJ 2006;332:1302–5
McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase. A systematic review of the
observational studies of selective and nonselective inhibitors of cyclooxygenase JAMA 2006;296:1633–44
NPS. National Prescribing Service Newsletter. Analgesic options for pain relief. No.47. 2006. Sótt 9 september
2009 á vef: http://www.nps.org.au/__data/assets/pdf_file/0017/23822/news47.pdf
Huerta C, et al. Nonsteroidal anti-inflammatory drugs and risk of first hospital admission for heart failure in the
general population. Heart. 22 may.2006; doi:10.1136/hrt.2005.082388. Sótt 9 september 2009 á vef:
http://heart.bmj.com/cgi/content/short/hrt.2005.082388v1
Scott, P. A, Kingsley, G. H., Scott, D. L (2008). Non-steroidal anti-inflammatory drugs and cardiac failure:
meta-analyses of observational studies and randomised controlled trials. Eur J Heart Fail 10: 1102-1107. Sótt 9
september 2009 á vef: http://eurjhf.oxfordjournals.org/cgi/content/abstract/10/11/1102
Drug Safety Update: Volume 2 Issue 7, February 2009. Sótt 10 september 2009 á vef:
http://www.mhra.gov.uk/Publications/Safetyguidance/DrugSafetyUpdate/CON038625
Loke YK, Trivedi AN, Singh S. Meta-analysis: gastrointestinal bleeding due to interaction between selective
serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2008;27:31–
40. http://www3.interscience.wiley.com/journal/119401152/abstract?CRETRY=1&SRETRY=0
Silverstein FE, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for
osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term
Arthritis Safety Study. JAMA. 2000;284:1247-55.
http://www.annals.org/cgi/ijlink?linkType=ABST&journalCode=jama&resid=284/10/1247
Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper
gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.
N Engl J Med. 2000;343:1520-8, 2 p following 1528. Sótt 14 september 2009 á vef:
http://www.annals.org/cgi/ijlink?linkType=ABST&journalCode=nejm&resid=343/21/1520
Rostom A, Dubé C, Jolicoeur E, Boucher M, Joyce J. Gastroduodenal ulcers associated with the use of nonsteroidal anti-inflammatory drugs: a systematic review of preventative pharmacological interventions. Ottawa,
Canada: Canadian Coordinating Office for Health Technology Assessment; 2004. Technology report no. 38.
Wilcox CM, et al. Consensus development conference on the use of nonsteroidal anti-infl ammatory agents,
including cyclooxygenase-2 inhibitors and aspirin. Clin Gastroenterol Hepatol 2006;4:1082–89.
Antman EM, Bennett JS, Daughtery A, Furberg C, Roberts H,Taubert KA. Use of nonsteroidal anti-infl
ammatory drugs: an update for clinicians: a scientific statement from the American
Heart Association. Circulation 2007;115:1634–42.
Fendrick AM. Summing the risk of NSAID therapy. Lancet 2007;369:9573:1580–1.
Beinþynningarlyf (M05BA.., M05BB..)
National Institute for Clinical Excellence (NICE). NICE technology appraisal. TA161 Osteoporosis secondary prevention including strontium ranelate Oct 2008 http://www.nice.org.uk/Guidance/TA161
National Institute for Clinical Excellence (NICE). NICE technology appraisal. TA160. Osteoporosis - primary
prevention Oct 2008 http://www.nice.org.uk/Guidance/TA160
Cranney A, Horsley T, O'Donnell S, et al. Effectiveness and safety of vitamin D in relation to bone health.
Evidence Report/Technology Assessment. Number 158. AHRQ Publication No. 07-E013. Rockville, MD:
Agency for Healthcare Research and Quality, 2007. http://www.ahrq.gov/clinic/tp/vitadtp.htm
Lothian Joint Formulary. Adult Formulary Update: January 2009. 6.6 Drugs affecting bone metabolism. Sótt 20
ágúst 2009 á vef http://www.ljf.scot.nhs.uk/exist/xmldb/db/ljf_v2/unified/unified6_6.xml
6
Landlæknisembættið
Gæða- og lýðheilsusvið/Heilbrigðistölfræðisvið
21. apríl 2010
Flicker L, MacInnis RJ, Stein MS, et al. Should older people in residential care receive vitamin D to prevent
falls? Results of a randomized trial. J Am Geriatr Soc 2005;53:1881–8.
NPS Prescribing Service. Alendronate with cholecalciferol (vitamin D3) (Fosamax Plus) — Vitamin D
deficiency and supplementationPublished 1 December 2008
http://www.nps.org.au/health_professionals/publications/nps_radar/current/december_2008/alendronate_with_
cholecalciferol/alendronate_with_cholecalciferol_webextra_1
NPS Prescribing Practice Review 39: Preventing osteoporosis and reducing fracture risk. 01/09/2007
http://www.nps.org.au/health_professionals/publications/prescribing_practice_review/current/preventing_osteo
porosis_and_reducing_fracture_risk
Osteoporosis Australia. Risks and benefits of sun exposure position statement. Sydney: Osteoporosis Australia,
2005.Sótt 23 ágúst á vef: http://www.osteoporosis.org.au/files/research/Sunexposure_OA_2007.pdf
Stevenson M, Lloyd Jones M, De Nigris E, Brewer N, Davis S, Oakley J. A systematic review and economic
evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment
of postmenopausal osteoporosis. Health Technol Assess 2005;9(22).Sótt 23 ágúst á vef:
http://www.hta.ac.uk/fullmono/mon922.pdf
Wells G, et al. Bisphosphonates for the primary and secondary prevention of osteoporotic fractures in
postmenopausal women: a meta-analysis (Technology report no 69). Ottawa: Canadian Agency for Drugs and
Technologies in Health, 2006.Sótt 23 ágúst á vef:
http://www.cadth.ca/media/pdf/371_Bisphosphonates_tr_e_NoAppendix.pdf
Lyles K et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007; 357.
Published on line on September 17th 2007. (the HORIZON recurrent fracture trial). Sótt 14 september 2009 á
vef: http://content.nejm.org/cgi/content/abstract/NEJMoa074941v1
Black, D. M.et al.for the FLEX Research Group, (2006). Effects of Continuing or Stopping Alendronate After
5 Years of Treatment: The Fracture Intervention Trial Long-term Extension (FLEX): A Randomized Trial.
JAMA 296: 2927-2938
Colon-Emeric, C. S. (2006). Ten vs Five Years of Bisphosphonate Treatment for Postmenopausal
Osteoporosis: Enough of a Good Thing. JAMA 296: 2968-2969
Reginster, J-Y, et al. (2006). Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal
osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis 65: 654-661
Geðrofslyf- sefandi lyf (N05A..)
Banerjee, S. The use of antipsychotic medication for people with dementia: Time for action. A report for the
Minister of State for Care Services. Department of Health. 12 November 2009. Sótt 14 desember 2009 á vef:
http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_108303
Hulstaert F, Thiry N, Eyssen M, Vrijens F. Pharmaceutical and non-pharmaceutical interventions for
Alzheimer’s Disease, a rapid assessment. Health Technology Assessment (HTA). Brussel: Belgian Health Care
Knowledge Centre (KCE); 2009. KCE reports 111C (D/2009/10.273/29). Sótt 20 ágúst 2009 á vef:
http://www.kce.fgov.be
Clive Ballard C, ML Hanney, Theodoulou M, et al. The dementia antipsychotic withdrawal trial (DART-AD):
long-term follow-up of a randomised placebo-controlled trial. Lancet Neurology 2009; Early Online
Publication, 9 January
http://www.nhs.uk/news/2009/01January/Pages/Dementiadrugdanger.aspx
Efficacy and Comparative Effectiveness of Off-Label Use of Atypical Antipsychotics Effective Health Care
(AHRQ) Jan 2007. http://effectivehealthcare.ahrq.gov/healthInfo.cfm?infotype=rr&ProcessID=5&DocID=64
MeReC Monthly no.12 March 2009 http://www.npc.co.uk/ebt/merec/cns/schiz/merec_monthly_no12.html
Þunglyndislyf (N06A..)
National Institute for Clinical Excellence. The management of bipolar disorder in adults, children and
adolescents, in primary and secondary care. National Institute for Clinical Excellence. 2006; Jul.
http://www.nice.org.uk/page.aspx?o=CG38
Scottish Intercollegiate Guidelines Network (SIGN). Bipolar affective disorder: A national clinical guideline.
2005; May. Sótt 18 ágúst á vef http://www.sign.ac.uk/pdf/qrg82.pdf
Yuan Y, Tsoi K, Hunt RH. Selective serotonin reuptake inhibitors and risk of upper GI bleeding: confusion or
confounding? Am J Med 2006;119:719–27.
Yatham LN et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the
management of patients with bipolar disorder: consensus and controversies. Bipolar Disorders. 2005; 7 (3): 569. Sótt 20 ágúst á vef http://www.canmat.org/resources/PDF/Bipolar_Guidelines.pdf
7
Landlæknisembættið
Gæða- og lýðheilsusvið/Heilbrigðistölfræðisvið
21. apríl 2010
Institute for Clinical Systems Improvement (ICSI). Major depression in adults in primary care. Bloomington
(MN): Institute for Clinical Systems Improvement (ICSI); May 2008. Sótt 20 ágúst á vef
http://www.icsi.org/for_patients_families/major_depression_in_adults_in_primary_care__for_patients___famil
ies__2.html
Lothian Joint Formulary. Adult Formulary Update: January 2009. 4.3 Drug treatment of major depression. Sótt
28 ágúst 2009 á vef http://www.ljf.scot.nhs.uk/exist/xmldb/db/ljf_v2/unified/unified4_3.xml
Comparative Effectiveness of Second-Generation Antidepressants in the Pharmacologic Treatment of Adult
Depression Effective Health Care (AHRQ) Jan 2007.
http://effectivehealthcare.ahrq.gov/healthInfo.cfm?infotype=rr&ProcessID=7&DocID=61
MeReC Extra No. 18: Escitalopram or citalopram for depression in primary care?,
http://www.npc.co.uk/ebt/merec/cns/depression/resources/merec_extra_no18.pdf
Do Single Stereoisomer Drugs Provide Value? Therapeutics Letter no. 45 June - September 2002
http://www.ti.ubc.ca/pages/letter45.htm
The Health Resources Commission. Office for Oregon Health Policy & Research. Second Generation
Antidepressants.DRAFT- Update 4. January 2009. Sótt 3 október 2009 á vef:
http://www.oregon.gov/OHPPR/HRC/docs/HRC.Reports/AntiDepressantsDraftupdate_4.pdf
Valdir opinberir staðir sem fjalla sérlega um aukaverkanir
Lyfjastofnun www.lyfjastofnun.is
Food and Drug Administration www.fda.gov og www.FDA.gov/medwatch
National Patient Safety Agency. UK. NHS
http://www.npsa.nhs.uk/nrls/medication-zone/medication-guidance /
Medical Product Agency
http://www.mpa.se/lakemedel/ie_lakeindex.html
Canadian Adverse Drug Reaction Newsletter http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/index-eng.php
8